RNA Technologies Enabling Drug Discovery and Development

Redefining the Future of Healthcare through Groundbreaking RNA Therapies

USD 4,950.00

* Required Fields

USD 4,950.00

PAY BY INVOICE

Be the first to review this product

This research service encompasses a comprehensive analysis of RNA therapy industry from the following perspectives:•     Industry Drivers and Challenges•     Technology Snapshot and Trends•     Clinical Pipeline Analysis•     Overview of the IP Landscape•     Innovator Profiles•     Future RoadmapThe RNA therapy platforms covered include:•     Splice-Switching Oligonucletides (SSO)•     Other Anti-Sense Oligonucleotide (ASO)•     Aptamers•     R

Table of Contents

1.0 Executive Summary1.1 Research Scope: RNA Therapies Redefining the Healthcare Landscape1.2 Analysis Framework: Frost & Sullivan’s Core Value1.3 Research Methodology: Five Steps Towards Success1.4 Key Findings2.0 RNA Therapies: Industry Overview2.1 RNA is the Rising Star of Transformative Therapy Platforms2.2 Industry Accelerators and Challenges2.3 RNA Delivery: Technology Segmentation2.4 RNA Therapies: Technology Segmentation2.5 Molecular Insights Across RNA Therapy3.0 Technology Trends & Clinical Pipeline3.1 Alternative Splicing Induced by SSO Therapies3.2 Clinical Pipeline Analysis for SSO Therapies for SMA and DMD3.3 Post-transcriptional Modifications by ASO3.4 Clinical Pipeline Overview for ASO Therapies3.5 Emerging Clinical Pipeline for ASO Therapies3.6 Early Phase ASO Therapies3.7 Inhibition of Ligand Binding by Aptamer3.8 Clinical Pipeline Analysis for Aptamer Therapies3.9 Landmark Year for RNA Interference Therapy Platform3.10 Clinical Analysis of RNA Interference Therapeutics3.11 Overview of the Emerging Landscape for mRNA Therapies3.12 Clinical Pipeline Analysis of mRNA Therapies3.13 saRNA: The Rising Participant in RNA-based Therapies4.0 Overview of The Patent Landscape4.1 Patenting Trends for ASO Technologies4.2 Patenting Trends for RNAi Platforms4.3 Patenting Trends for mRNA Technologies5.0 Innovation Profiles5.1 Targeted RNAi Technology for Enhanced Disease Management5.2 Enabling Targeted Delivery of RNAi Therapeutics5.3 Developing Stable and Non-immunogenic mRNA Therapies5.4 Fueling Novel RNA Therapy and Delivery Platforms5.5 Enabling Potent Antisense Therapeutics 6.0 Future Perspectives6.1 RNA Platforms likely to Transform the Future of Health & Wellness6.2 Navigating Through The Future Landscape for RNA Technologies7.0 Growth Opportunities and Companies to Action7.1 Growth Opportunity 1: ASO Therapies7.2 Growth Opportunity 2: RNAi Therapies7.3 Growth Opportunity 3: mRNA Therapies7.4 Strategic Imperatives for Success and Growth 8.0 Key Industry Influencers8.1 Industry Interactions8.1 Industry Interactions (continued)Legal Disclaimer




Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.